[go: up one dir, main page]

BRPI0411762A - derivados de difenilpiridina, seu preparo e sua aplicação em terapêutica - Google Patents

derivados de difenilpiridina, seu preparo e sua aplicação em terapêutica

Info

Publication number
BRPI0411762A
BRPI0411762A BRPI0411762-0A BRPI0411762A BRPI0411762A BR PI0411762 A BRPI0411762 A BR PI0411762A BR PI0411762 A BRPI0411762 A BR PI0411762A BR PI0411762 A BRPI0411762 A BR PI0411762A
Authority
BR
Brazil
Prior art keywords
preparation
application
substituted
diphenylpyridine
alkyl group
Prior art date
Application number
BRPI0411762-0A
Other languages
English (en)
Inventor
Francis Barth
Laurent Hortala
Murielle Rinaldi-Carmona
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of BRPI0411762A publication Critical patent/BRPI0411762A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Addiction (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

"DERIVADOS DE DIFENILPIRIDINA, SEU PREPARO E SUA APLICAçãO EM TERAPêUTICA". A presente invenção refere-se aos derivados de 5,6-difenilpiridina-3-carboxamida, de fórmula geral (I): na qual: R~ 1~ representa o hidrogênio ou UM (C~ 1~-C~ 4~) alquila; R~ 2~ representa: um radical heterocíclico mononitrogenado, saturado, de 5 a 7 átomos de, o átomo de nitrogênio sendo substituído por um grupo (C~ 1~C~ 4~)alcanoíla; um grupo NR~ 10~R~ 11~; um radical carbocíclico não-aromático em C~ 3~-C~ 10~ substituído mais de 3 vezes por um grupo (C~ 1~-C~ 4~) alquila; . um radical carbocíclico não-aromático em C~ 11~-C~ 12~, não-substituído ou substituído uma ou várias vezes por um grupo (C~ 1~-C~ 4~)alquila; . um radical heterocíclico monooxigenado, saturado de 5 a 7 átomos, substituído mais de 3 vezes por um grupo (C~ 1~-C~ 4~)alquila; - ou R~ 1~ e R~ 2~ juntamente com o átomo de nitrogênio ao qual são ligados constituem um radical piperidin-1-ila dissubstituído em 4-assim como seus sais, seus solvatos e seus hidratos. Processo de preparo e aplicação em terapêutica.
BRPI0411762-0A 2003-06-26 2004-06-24 derivados de difenilpiridina, seu preparo e sua aplicação em terapêutica BRPI0411762A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0307757A FR2856684B1 (fr) 2003-06-26 2003-06-26 Derives de diphenylpyridine, leur preparation et leur application en therapeutique
PCT/FR2004/001581 WO2005000817A2 (fr) 2003-06-26 2004-06-24 Derives de diphenylpyridine, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
BRPI0411762A true BRPI0411762A (pt) 2006-08-08

Family

ID=33515448

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0411762-0A BRPI0411762A (pt) 2003-06-26 2004-06-24 derivados de difenilpiridina, seu preparo e sua aplicação em terapêutica

Country Status (16)

Country Link
US (1) US7345059B2 (pt)
EP (1) EP1641758B1 (pt)
JP (1) JP4669839B2 (pt)
KR (1) KR20060025191A (pt)
CN (1) CN1832945A (pt)
AR (1) AR044906A1 (pt)
AT (1) ATE412635T1 (pt)
AU (1) AU2004251914B9 (pt)
BR (1) BRPI0411762A (pt)
CA (1) CA2528619A1 (pt)
DE (1) DE602004017463D1 (pt)
FR (1) FR2856684B1 (pt)
IL (1) IL172733A0 (pt)
MX (1) MXPA05014222A (pt)
TW (1) TW200504019A (pt)
WO (1) WO2005000817A2 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7271266B2 (en) 2002-03-28 2007-09-18 Merck & Co., Inc. Substituted 2,3-diphenyl pyridines
US7405221B2 (en) 2002-09-27 2008-07-29 Merck & Co., Inc. Substituted pyrimidines
MX2007012213A (es) 2005-04-06 2007-12-10 Hoffmann La Roche Derivados de piridin-3-carboxamida como agonistas inversos de canabinoides.
GB0514739D0 (en) * 2005-07-19 2005-08-24 Astrazeneca Ab Therapeutic agents
WO2007039797A1 (en) * 2005-10-03 2007-04-12 Pfizer Products Inc. Use of cannabinoid receptor-1 antagonist for treating inflammation and arthritis
FR2899899A1 (fr) * 2006-04-14 2007-10-19 Sanofi Aventis Sa Derives d'aminomethyl pyridine, leur preparation et leur application en therapeutique
US7629346B2 (en) 2006-06-19 2009-12-08 Hoffmann-La Roche Inc. Pyrazinecarboxamide derivatives as CB1 antagonists
FR2904827B1 (fr) 2006-08-11 2008-09-19 Sanofi Aventis Sa Derives de 5,6-bisaryl-2-pyridine-carboxamide, leur preparation et leur application en therapeutique comme antiganistes des recepteurs a l'urotensine ii
US7781593B2 (en) 2006-09-14 2010-08-24 Hoffmann-La Roche Inc. 5-phenyl-nicotinamide derivatives
FR2927330B1 (fr) * 2008-02-07 2010-02-19 Sanofi Aventis Derives de 5,6-bisaryl-2-pyridine-carboxamide, leur preparation et leur application en therapeutique comme antagonistes des recepteurs a l'urotensine ii
US8410107B2 (en) 2010-10-15 2013-04-02 Hoffmann-La Roche Inc. N-pyridin-3-yl or N-pyrazin-2-yl carboxamides
US8669254B2 (en) 2010-12-15 2014-03-11 Hoffman-La Roche Inc. Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents
CN102276517B (zh) * 2011-06-29 2012-11-28 孙光辉 二芳基吡啶类药物的合成方法
EP2903978B1 (en) 2012-10-05 2022-12-07 Rigel Pharmaceuticals, Inc. Gdf-8 inhibitors
WO2017195703A1 (ja) * 2016-05-09 2017-11-16 日本曹達株式会社 環状アミン化合物および有害生物防除剤
EP3484856B1 (en) 2016-07-12 2023-11-15 Revolution Medicines, Inc. 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors
SG11201906412SA (en) * 2017-01-23 2019-08-27 Revolution Medicines Inc Pyridine compounds as allosteric shp2 inhibitors
CA3051206A1 (en) 2017-01-23 2018-07-26 Revolution Medicines, Inc. Bicyclic compounds as allosteric shp2 inhibitors
AU2018328273A1 (en) 2017-09-07 2020-03-12 Revolution Medicines, Inc. SHP2 inhibitor compositions and methods for treating cancer
JP2020536881A (ja) 2017-10-12 2020-12-17 レヴォリューション・メディスンズ，インコーポレイテッド アロステリックｓｈｐ２阻害剤としてのピリジン、ピラジンおよびトリアジン化合物
KR20200099530A (ko) 2017-12-15 2020-08-24 레볼루션 메디슨즈, 인크. 알로스테릭 shp2 억제제로서의 다환식 화합물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2198737B1 (pt) * 1972-09-13 1975-11-28 Serdex
FR2248027B2 (pt) * 1973-10-18 1977-09-09 Serdex
FR2612189B1 (fr) * 1987-03-13 1989-06-23 Roussel Uclaf Nouveaux derives de la pyridine, leur procede de preparation et les nouveaux intermediaires obtenus, leur application a titre de medicaments et les compositions les renfermant
GB9210436D0 (en) * 1992-05-15 1992-07-01 Neave Andrew J A light projector for use in conjunction with light guides
FR2741621B1 (fr) * 1995-11-23 1998-02-13 Sanofi Sa Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant
FR2816938B1 (fr) * 2000-11-22 2003-01-03 Sanofi Synthelabo Derives de 3-aroylindole, leur procede de preparation et les compositions pharmaceutiques en contenant
US7271266B2 (en) * 2002-03-28 2007-09-18 Merck & Co., Inc. Substituted 2,3-diphenyl pyridines
FR2838438A1 (fr) * 2002-04-11 2003-10-17 Sanofi Synthelabo Derives de diphenylpyridine,leur preparation, les compositions pharmaceutiques en contenant
FR2838439B1 (fr) * 2002-04-11 2005-05-20 Sanofi Synthelabo Derives de terphenyle, leur preparation, les compositions pharmaceutqiues en contenant

Also Published As

Publication number Publication date
WO2005000817A3 (fr) 2005-03-17
CN1832945A (zh) 2006-09-13
AU2004251914B9 (en) 2010-02-25
AR044906A1 (es) 2005-10-05
DE602004017463D1 (de) 2008-12-11
FR2856684B1 (fr) 2008-04-11
JP4669839B2 (ja) 2011-04-13
US7345059B2 (en) 2008-03-18
FR2856684A1 (fr) 2004-12-31
ATE412635T1 (de) 2008-11-15
US20060189664A1 (en) 2006-08-24
IL172733A0 (en) 2006-04-10
TW200504019A (en) 2005-02-01
JP2007514638A (ja) 2007-06-07
AU2004251914A1 (en) 2005-01-06
WO2005000817A2 (fr) 2005-01-06
EP1641758B1 (fr) 2008-10-29
KR20060025191A (ko) 2006-03-20
AU2004251914B2 (en) 2010-01-07
CA2528619A1 (fr) 2005-01-06
EP1641758A2 (fr) 2006-04-05
MXPA05014222A (es) 2006-03-13

Similar Documents

Publication Publication Date Title
BRPI0411762A (pt) derivados de difenilpiridina, seu preparo e sua aplicação em terapêutica
BRPI0607577A2 (pt) antagonistas cgrp, processo para sua preparação bem como seu uso como medicamento
PE20020476A1 (es) Derivados de glucopiranosiloxibencilbenceno y composiciones farmaceuticas que comprenden los mismos
NO20076680L (no) Utvalgte CGRP-antagonister, metoder for fremstilling av disse og deres anvendelse som medikamenter
BRPI0606644A2 (pt) derivados de 4-carboxamida tiazola
NO20073325L (no) Nye naftalenforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem
NO972881L (no) Piperazinderivater, legemidler som inneholder disse, anvendelse derav og fremgangsmåte for deres fremstilling
BR0317455A (pt) Derivados de pirrol-pirazol substituìdos como inibidores de quinase
ECSP034707A (es) Derivados de urea como antagonistas de alfa integrado
BR112012007069A2 (pt) derivado de fenol
CO5690593A2 (es) Nuevos derivados de pirimidin 2-amina
BR112012021556A2 (pt) processo para a preparação de peptídeos prolila substituídos e peptidomiméticos similares
BR0316609A (pt) Sinomenina e compostos de sinomenina, sìntese e uso
NO20083480L (no) Piperidinoylpyrrolidiner som melanokortin type 4 reseptor agonister
BRPI0515133A (pt) derivados de uréia como bloqueadores do canal de cálcio
TW200800962A (en) Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
BRPI0900983B8 (pt) composto de diometina, processo para a síntese do mesmo, composição farmacêutica e seu uso
BRPI0813809A2 (pt) derivados de 7-alquinil -1,8-naftiridonas, sua preparação e sua aplicação em terapêutica.
BRPI0413467A (pt) aminopironas e seu uso como inibidoras da atm
BR0313727A (pt) Derivados de isoquinolina como inibidores de metaloproteinase da matriz
BRPI0406500A (pt) processo farmacêutico e compostos preparados pelo mesmo
BR0308765A (pt) Compostos (4,2-dissubstituìdo-tiazol-5-il)amina como inibidores de pde7
BR0313179A (pt) Pró-drogas de (n-2-piridil-n-2-hidroxicarboniletil)-amida de ácido 1-metil-2-(4-amidinofenilaminometil)-benzimidazol-5-il -carboxìlico, sua preparação e seu emprego como medicamento
BR0313734A (pt) Derivados do tiofeno, o seu processo de preparação e as composições farmacêuticas que os contêm
NO20082698L (no) Nye derivater, deres salter og antisoppmidler inneholdende disse

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2259 DE 22/04/2014.